B-control	0	10	Aprepitant
O	11	17	versus
B-intervention	18	31	dexamethasone
O	32	35	for
O	36	46	preventing
B-condition	47	59	chemotherapy
I-condition	59	60	-
I-condition	60	67	induced
I-condition	68	75	delayed
I-condition	76	82	emesis
O	83	85	in
O	86	94	patients
O	95	99	with
O	100	106	breast
O	107	113	cancer
O	113	114	:
O	115	116	a
O	117	127	randomized
O	128	134	double
O	134	135	-
O	135	140	blind
O	141	146	study
O	146	147	.

O	148	149	A
O	150	161	combination
O	162	164	of
O	165	175	aprepitant
O	175	176	,
O	177	178	a
O	179	180	5
O	180	181	-
O	181	184	HT3
O	185	193	receptor
O	194	204	antagonist
O	204	205	,
O	206	209	and
O	210	223	dexamethasone
O	224	226	is
O	227	238	recommended
O	239	242	for
O	243	246	the
O	247	258	prophylaxis
O	259	261	of
O	262	267	acute
O	268	270	or
O	271	278	delayed
O	279	285	emesis
O	286	293	induced
O	294	296	by
O	297	309	chemotherapy
O	310	320	containing
O	321	335	anthracyclines
O	336	340	plus
O	341	357	cyclophosphamide
O	358	360	in
O	361	369	patients
O	370	374	with
O	375	381	breast
O	382	388	cancer
O	388	389	.

O	390	393	The
O	394	397	aim
O	398	400	of
O	401	405	this
O	406	411	study
O	412	415	was
O	416	418	to
O	419	425	verify
O	426	433	whether
O	434	447	dexamethasone
O	448	450	is
O	451	459	superior
O	460	462	to
O	463	473	aprepitant
O	474	476	in
O	477	487	preventing
O	488	495	delayed
O	496	502	emesis
O	503	505	in
O	506	514	patients
O	515	524	receiving
O	525	528	the
O	529	533	same
O	534	545	prophylaxis
O	546	549	for
O	550	555	acute
O	556	562	emesis
O	562	563	.

O	564	565	A
O	566	576	randomized
O	577	583	double
O	583	584	-
O	584	589	blind
O	590	595	study
O	596	605	comparing
O	606	616	aprepitant
O	617	623	versus
O	624	637	dexamethasone
O	638	641	was
O	642	651	completed
O	652	654	in
B-eligibility	655	667	chemotherapy
I-eligibility	667	668	-
I-eligibility	668	673	naive
I-eligibility	674	682	patients
I-eligibility	683	687	with
I-eligibility	688	694	breast
I-eligibility	695	701	cancer
I-eligibility	702	709	treated
I-eligibility	710	714	with
I-eligibility	715	729	anthracyclines
I-eligibility	730	734	plus
I-eligibility	735	751	cyclophosphamide
O	751	752	.

O	753	759	Before
O	760	772	chemotherapy
O	772	773	,
O	774	777	all
O	778	786	patients
O	787	791	were
O	792	799	treated
O	800	804	with
O	805	816	intravenous
O	817	829	palonosetron
O	830	831	0
O	831	832	.
O	832	834	25
O	835	837	mg
O	837	838	,
O	839	852	dexamethasone
O	853	854	8
O	855	857	mg
O	857	858	,
O	859	862	and
O	863	867	oral
O	868	878	aprepitant
O	879	882	125
O	883	885	mg
O	885	886	.

O	887	889	On
O	890	894	days
O	895	896	2
O	897	900	and
O	901	902	3
O	902	903	,
O	904	912	patients
O	913	921	randomly
O	922	930	received
O	931	935	oral
O	936	949	dexamethasone
O	950	951	4
O	952	954	mg
O	955	960	twice
O	961	964	per
O	965	968	day
O	969	971	or
O	972	982	aprepitant
O	983	985	80
O	986	988	mg
O	989	993	once
O	994	997	per
O	998	1001	day
O	1001	1002	.

O	1003	1010	Primary
O	1011	1014	end
O	1015	1020	point
O	1021	1024	was
B-outcome-Measure	1025	1029	rate
I-outcome-Measure	1030	1032	of
I-outcome-Measure	1033	1041	complete
I-outcome-Measure	1042	1050	response
O	1051	1052	(
O	1052	1054	ie
O	1054	1055	,
O	1056	1058	no
O	1059	1067	vomiting
O	1068	1070	or
O	1071	1077	rescue
O	1078	1087	treatment
O	1087	1088	)
O	1089	1093	from
O	1094	1098	days
O	1099	1100	2
O	1101	1103	to
O	1104	1105	5
O	1106	1111	after
O	1112	1124	chemotherapy
O	1124	1125	.

O	1126	1128	Of
B-total-participants	1129	1132	580
O	1133	1141	enrolled
O	1142	1150	patients
O	1150	1151	,
B-total-participants	1152	1155	551
O	1156	1160	were
O	1161	1170	evaluable
O	1170	1171	:
B-intervention-participants	1172	1175	273
O	1176	1184	received
O	1185	1198	dexamethasone
O	1198	1199	,
O	1200	1203	and
B-control-participants	1204	1207	278
O	1208	1216	received
O	1217	1227	aprepitant
O	1227	1228	.

B-outcome	1229	1232	Day
I-outcome	1233	1234	1
I-outcome	1235	1243	complete
I-outcome	1244	1252	response
I-outcome	1253	1258	rates
O	1259	1263	were
O	1264	1271	similar
O	1271	1272	:
B-iv-bin-percent	1273	1275	87
I-iv-bin-percent	1275	1276	.
I-iv-bin-percent	1276	1277	6
I-iv-bin-percent	1277	1278	%
O	1279	1282	for
O	1283	1296	dexamethasone
O	1297	1300	and
B-cv-bin-percent	1301	1303	84
I-cv-bin-percent	1303	1304	.
I-cv-bin-percent	1304	1305	9
I-cv-bin-percent	1305	1306	%
O	1307	1310	for
O	1311	1321	aprepitant
O	1322	1323	(
O	1323	1324	P
O	1325	1326	<
O	1327	1328	.
O	1328	1330	39
O	1330	1331	)
O	1331	1332	.

O	1333	1337	From
B-outcome	1338	1342	days
I-outcome	1343	1344	2
I-outcome	1345	1347	to
I-outcome	1348	1349	5
I-outcome	1349	1350	,
I-outcome	1351	1359	complete
I-outcome	1360	1368	response
I-outcome	1369	1374	rates
O	1375	1379	were
O	1380	1383	the
O	1384	1388	same
O	1389	1393	with
O	1394	1398	both
O	1399	1409	antiemetic
O	1410	1421	prophylaxes
O	1422	1423	(
O	1423	1425	79
O	1425	1426	.
O	1426	1427	5
O	1427	1428	%
O	1428	1429	;
O	1430	1431	P
O	1432	1433	<
O	1434	1435	1
O	1435	1436	.
O	1436	1438	00
O	1438	1439	)
O	1439	1440	,
O	1441	1443	as
O	1444	1448	were
O	1449	1456	results
O	1457	1459	of
O	1460	1469	secondary
O	1470	1473	end
O	1474	1480	points
O	1481	1482	(
O	1482	1484	ie
O	1484	1485	,
B-outcome	1486	1494	complete
I-outcome	1495	1505	protection
O	1505	1506	,
B-outcome	1507	1512	total
I-outcome	1513	1520	control
O	1520	1521	,
B-outcome	1522	1524	no
I-outcome	1525	1533	vomiting
O	1533	1534	,
B-outcome	1535	1537	no
I-outcome	1538	1544	nausea
O	1544	1545	,
B-outcome	1546	1551	score
I-outcome	1552	1554	of
I-outcome	1555	1565	Functional
I-outcome	1566	1572	Living
I-outcome	1573	1578	Index
I-outcome	1578	1579	-
I-outcome	1579	1585	Emesis
O	1585	1586	;
O	1587	1588	P
O	1589	1590	<
O	1591	1592	.
O	1592	1594	24
O	1594	1595	)
O	1595	1596	.

B-outcome	1597	1607	Incidences
I-outcome	1608	1610	of
I-outcome	1611	1619	insomnia
O	1620	1621	(
B-iv-bin-percent	1621	1622	2
I-iv-bin-percent	1622	1623	.
I-iv-bin-percent	1623	1624	9
I-iv-bin-percent	1624	1625	%
O	1626	1627	v
B-cv-bin-percent	1628	1629	0
I-cv-bin-percent	1629	1630	.
I-cv-bin-percent	1630	1631	4
I-cv-bin-percent	1631	1632	%
O	1632	1633	;
O	1634	1635	P
O	1636	1637	<
O	1638	1639	.
O	1639	1641	02
O	1641	1642	)
O	1643	1646	and
B-outcome	1647	1656	heartburn
O	1657	1658	(
B-iv-bin-percent	1658	1659	8
I-iv-bin-percent	1659	1660	.
I-iv-bin-percent	1660	1661	1
I-iv-bin-percent	1661	1662	%
O	1663	1664	v
B-cv-bin-percent	1665	1666	3
I-cv-bin-percent	1666	1667	.
I-cv-bin-percent	1667	1668	6
I-cv-bin-percent	1668	1669	%
O	1669	1670	;
O	1671	1672	P
O	1673	1674	<
O	1675	1676	.
O	1676	1678	03
O	1678	1679	)
O	1680	1684	were
O	1685	1698	significantly
O	1699	1706	greater
O	1707	1711	with
O	1712	1725	dexamethasone
O	1726	1728	on
O	1729	1733	days
O	1734	1735	2
O	1736	1738	to
O	1739	1740	5
O	1740	1741	.

O	1742	1744	In
O	1745	1753	patients
O	1754	1758	with
O	1759	1765	breast
O	1766	1772	cancer
O	1773	1780	treated
O	1781	1785	with
O	1786	1799	anthracycline
O	1800	1804	plus
O	1805	1821	cyclophosphamide
O	1822	1834	chemotherapy
O	1835	1838	and
O	1839	1848	receiving
O	1849	1852	the
O	1853	1857	same
O	1858	1868	antiemetic
O	1869	1880	prophylaxis
O	1881	1884	for
O	1885	1890	acute
O	1891	1897	emesis
O	1897	1898	,
O	1899	1912	dexamethasone
O	1913	1916	was
O	1917	1920	not
O	1921	1929	superior
O	1930	1932	to
O	1933	1943	aprepitant
O	1944	1947	but
O	1948	1955	instead
O	1956	1959	had
O	1960	1967	similar
O	1968	1976	efficacy
O	1977	1980	and
O	1981	1989	toxicity
O	1990	1992	in
O	1993	2003	preventing
O	2004	2011	delayed
O	2012	2018	emesis
O	2018	2019	.
